65,437 trials
Breast Neoplasms
Primary: Part A: Clinical Benefit (CB) Assessed by Complete Response (CR), Partial Response (PR) or Stable Disease (SD) for at Least 6 Months Using the Response Evaluation…
Hemorrhage
Primary: Reversal of Dabigatran-induced Prolongation of Blood Coagulation Time — 0.0; 100.0; 0.0; 100.0 percentage of participants
FGFR Inhibition, Pharmacokinetics, Biomarkers · ER+ Breast Cancer
Primary: Safety and Tolerability in Terms of Number of Patients With Adverse Events (Serious and Non-serious) — 5; 5; 12; 9 Participants
Osteoporosis · Humoral Hypercalcemia of Malignancy · Hyperparathyroidism
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 2; 2 participants
Post-stroke Spasticity of the Upper Limb
Primary: Change From Baseline in Ashworth Scale (AS) Score of Primary Target Clinical Pattern — -0.9; -0.5 units on a scale — p=<0.001
Prevention of Meningococcal Disease
Primary: Number of Subjects (2-10 Years of Age) With Human Serum Bactericidal Activity (hSBA) Titers ≥1:4 After Receiving Either MenACWY-CRM or MenACWY-PS Vaccine — 6; 1; 228…
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events in Part 1 and Part 2 — 16.7; 0.0; 0.0; 0.0 Percentage of participants
Dental Caries · Dental Pulp Exposure
Primary: Comparison of MTA/FS Pulpotomy Versus RCT Treated Incisors With Acceptable Radiographic Outcome at 12 Months Post-procedure. — .97; .92 Proportion of incisors — p=.15
Cytomegalovirus Infections
Primary: Proportion of Patients Developing Cytomegalovirus (CMV) Disease Within 6 Months of Liver Transplantation Under Valcyte Prophylaxis — 3 participants
Advanced Solid Malignancies
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Parkinson Disease
Primary: Change From Baseline in Mean "Off" Time — -0.9; -0.9; -0.8; -0.8 Hours/day — p=0.8700
Acute Myeloid Leukemia With FLT3/ITD Mutation · Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 · Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
Primary: Overall Survival (OS) Rate — 62; 71 percentage of participants
Advanced Pancreatic Neuroendocrine Tumor · Locally Advanced Pancreatic Neuroendocrine Tumor · Pancreatic Gastrinoma
Primary: Progression Free Survival — 14.0; 16.7 months — p=0.12
Lung Cancer
Primary: To Establish Rate of Non-progressive Disease at 4 Months in Patients With Advanced NSCLC Who Have Been Designated PS2 by Their Treating Physician — 28 percentage of…
Lung Cancer
Primary: 8-Week Disease Control Rate — 58.2 percentage of participants